Robyn Schecter
Montreal, QC H9S1A9, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
Journal: Journal of medical economics
Published: October 20, 2020
Diagnosis and management of secondary-progressive multiple sclerosis: time for change.
Journal: Neurodegenerative disease management
Published: November 27, 2019
The clinical and cost impact of switching to fingolimod versus other first line injectable disease-modifying therapies in patients with relapsing multiple sclerosis.
Journal: Current medical research and opinion
Published: January 08, 2019
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approaches.
Journal: Neural regeneration research
Published: September 21, 2018
A retrospective claims analysis: Compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies.
Journal: PloS one
Published: August 14, 2018
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatment.
Journal: Current medical research and opinion
Published: March 28, 2018
Canadian Experience with Fingolimod: Adherence to Treatment and Monitoring.
Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: February 19, 2016
Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Journal: The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
Published: November 28, 2015
Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Journal: Current medical research and opinion
Published: May 08, 2013
Showing 1-9 of 9
Last Updated: 09/26/2026